Premium
Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide
Author(s) -
Sonoyama Takuhiro,
Tamura Naohisa,
Miyashita Kazutoshi,
Park Kwijun,
Oyamada Naofumi,
Taura Daisuke,
Inuzuka Megumi,
Fukunaga Yasutomo,
Sone Masakatsu,
Nakao Kazuwa
Publication year - 2009
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2009.05.025
Subject(s) - carbon tetrachloride , hepatic stellate cell , hepatic fibrosis , fibrosis , medicine , brain natriuretic peptide , endocrinology , genetically modified mouse , ccl4 , transforming growth factor , intraperitoneal injection , chemistry , transgene , pathology , heart failure , biochemistry , gene , organic chemistry
Anti‐fibrotic and organ protective effects of brain natriuretic peptide (BNP) have been reported. In this study, effects of BNP on liver fibrosis were examined in the carbon tetrachloride (CCl 4 )‐induced liver fibrosis model using BNP‐transgenic (Tg) and wild‐type (WT) mice. Twice‐a‐week intraperitoneal injections of CCl 4 for 8 weeks resulted in massive liver fibrosis, augmented transforming growth factor (TGF)‐β 1 and type I procollagen α 1 chain (Col1a1) mRNA expression, and the hepatic stellate cell (HSC) activation in WT mice, all of which were significantly suppressed in Tg mice. These observations indicate that BNP inhibits liver fibrosis by attenuating the activation of HSCs.